7.16
-0.34 (-4.53%)
| Penutupan Terdahulu | 7.50 |
| Buka | 7.48 |
| Jumlah Dagangan | 66,466 |
| Purata Dagangan (3B) | 70,295 |
| Modal Pasaran | 205,237,360 |
| Harga / Jualan (P/S) | 40.44 |
| Harga / Buku (P/B) | 87.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -273.01% |
| EPS Cair (TTM) | -3.79 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,114.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 34.04% |
| Nisbah Semasa (MRQ) | 3.74 |
| Aliran Tunai Operasi (OCF TTM) | -22.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -15.27 M |
| Pulangan Atas Aset (ROA TTM) | -22.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -428.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Menaik |
| Diagnostics & Research (Global) | Menaik | Menaik | |
| Stok | Insight Molecular Diagnostics I | Menaik | - |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.63 |
|
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 22.47% |
| % Dimiliki oleh Institusi | 56.26% |
| Julat 52 Minggu | ||
| Median | 9.00 (25.70%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 11 Nov 2025 | 9.00 (25.70%) | Beli | 7.53 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring |
| 07 Jan 2026 | Pengumuman | iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation |
| 06 Jan 2026 | Pengumuman | iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch |
| 05 Jan 2026 | Pengumuman | iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion |
| 10 Nov 2025 | Pengumuman | IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |